Circassia pulls plug on AZ agreement
Circassia will shed its debt to AstraZeneca under the move
Read More
Tag: Circassia
Circassia’s COPD drug gets FDA approval
The approval is based on data from three Phase III studies, ACLIFORM, AUGMENT and AMPLIFY.
Read More
Circassia pays $32M for rights to AirNOvent
UK group Circassia has announced plans to acquire US and Chinese commercialisation rights to AirNOvent, a novel nitric oxide product, from AIT Therapeutics.
Read More
Circassia takes on full US rights to AZ’ Tudorza
Circassia Pharmaceuticals is exercising an option to acquire the full US commercial rights to AstraZeneca’s Tudorza.
Read More
Circassia abandons allergy programme after trial failure
British biotech Circassia has announced the death of its allergy programme following a second key trial failure, choosing to focus all of its efforts on its respiratory business instead.
Read More
Second US rejection for AZ’ potassium binder
AstraZeneca’s hyperkalaemia treatment ZS-9 has suffered another setback on the path to US approval having been rejected by regulators for the second time. The drug giant also unveiled a US-based partnership with Circassia for development and commercialisation of COPD drugs Turdoza and Duaklir.
Read More
Circassia’s cat allergy drug fails to hit trial targets
Shares in UK biotech Circassia have plummeted after its flagship experimental cat allergy drug failed to hit targets in a Phase III trial.
Read More
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
- Theolytics announces first patient dosed in the Octopod‑IP trial
- UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
- Saphnelo approved in the US for subcutaneous self‑administration
- Transgene completes randomisation in phase 2 trial of tg4050
